Allavena et al. (2005) and Martin-Broto et al. (2020) detailed an imaginative anti-tumor item, yondelis (trabectedin), which inhibited macrophage differentiation and cytokine yield in metastatic soft-tissue sarcoma, ovarian and breast adenocarcinoma. Takenaka et al. (2019) reported that the production of kynurenine by glioma activated aryl hydrocarbon receptor (AHR), which drove TAMs enrollment in response to CCL2 and suppressed NF-κB activation in TAMs to modulate their functions. The gene discussed is AHR; the disease is breast adenocarcinoma.